Developing a monoclonal antibody to fight Pseudomonas aeruginosa infections
Official title: Monoclonal Antibody to Combat Pseudomonas Aeruginosa
Funded at Emory University · NIH-10907581 · Data updated 2026-11-12
This study is testing a new treatment that uses a special antibody to help fight infections caused by a harmful germ called Pseudomonas aeruginosa, which can be a big problem for people with weakened immune systems, like those with cystic fibrosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $968,643 |
| NIH project number | 5R01AI176545-02 |
| Project ID | NIH-10907581 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are immunocompromised individuals, including those with cystic fibrosis or patients recovering from COVID-19 who are at risk of Pseudomonas aeruginosa infections.
✕Less likely to help
Patients with fully functioning immune systems or those not at risk for Pseudomonas aeruginosa infections may not benefit from this research.
What this research studies
This research focuses on creating a monoclonal antibody that targets a specific protein, elongation factor-Tu (EF-Tu), found on the surface of Pseudomonas aeruginosa, a harmful bacterium that often infects individuals with weakened immune systems. The study aims to evaluate the effectiveness of this antibody in preventing and treating infections caused by P. aeruginosa, particularly in hospital settings and among patients with cystic fibrosis. By using animal models, researchers will assess how well this antibody can help clear the infection and improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly reduces the severity and mortality of Pseudomonas aeruginosa infections.
How similar studies have gone: Previous research has shown promise in developing antibody therapies for bacterial infections, indicating potential success for this novel approach.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Goldberg, Joanna B — Emory University
- Study coordinator: Goldberg, Joanna B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.